{
  "docId": "019de076-86c0-778c-b811-8ed1a345f3e4",
  "docSlug": "3a23784462a131093cb118313f70597a",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 25,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses three charts: a bar chart for food intake and two line charts for body weight loss (BWL) in different mouse models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/18",
  "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4",
  "deckJsonHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4.json",
  "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Cumulative Food intake in HF-DIO Obese Mice DA-1726 vs Semaglutide",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b7eb66d-c8cc-4118-9734-d58888253bb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.63,
        "y": 0.32
      },
      "kind": "chart",
      "text": "BWL in HF-FATZO T2DM/Obese Mice DA-1726 vs Semaglutide",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2a240d4-34bd-4c3a-a8e2-3ef8f904970f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.31,
        "y": 0.32
      },
      "kind": "chart",
      "text": "BWL in HF-DIO Obese Mice DA-1726 vs Semaglutide",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4477c78-5126-4ac0-a867-059286a014be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "disclaimer",
      "text": "*Statistically significant compared to control. Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/Glucagon Receptor); HF-DIO (High Fat-Diet Induced Obesity); GLP-1 (Glucagon-Like Peptide 1). 1. Dong-A Study Report 104561. 2. Dong-A Study Report 104455. 3. Kim TH et al. 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b056555d-b8b7-4660-99a7-1d7cfdb9b5c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Weight loss observed from DA-1726 is attributed to reduced food intake via GLP1R and increased energy expenditure via the GCGR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c1196ab-93b1-4736-861d-18dd01f0282e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "title",
      "text": "DA-1726 outperformed Semaglutide (WEGOVY™), a GLP-1 agonist, in mouse models of obesity*",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1d87fe4-e9c3-48d4-a9ee-ebfa01e27e8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "DA-1726: Therapeutic Potential in Obesity (1-3) — Semaglutide Comparison",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c8efa54-ee3b-48fe-936d-353788ce6992",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}